Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive cell therapy across metastatic solid cancers
2017-002323-25Phase 2Completed
- Sponsor
- Center for Cancer Immune Therapy
- Start
- Jun 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MDA-TIL, nivolumab, ipilimumab, cyclophosphamide, fludarabine and 1 more in Nonhematologic neoplasms and eye cancer, sponsored by Center for Cancer Immune Therapy. Primary endpoint: Toxicity. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
Nonhematologic neoplasmseye cancer
Beyond the preview
Go deeper on 2017-002323-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002323-25.